Fosinopril Sodium And Hydrochlorothiazide

Risk of lithium toxicity increased due to reduced renal clearance from both ACE inhibitor and thiazide components; frequent serum lithium level monitoring recommended.

Injectable gold may cause nitritoid reactions (facial flushing, nausea, vomiting, hypotension) when used with fosinopril sodium and hydrochlorothiazide.

Antacid may impair absorption of fosinopril; dosing should be separated by 2 hours if concomitant use is necessary.

Potassium-sparing diuretic may increase risk of hyperkalemia when used with fosinopril sodium and hydrochlorothiazide; requires monitoring of serum potassium.

Drug Interactions Potassium supplements and potassium-sparing diuretics As noted above (“Derangements of Serum Electrolytes”), the net effect of fosinopril sodium and hydrochlorothiazide may be to elevate a patient’s serum potassium, to reduce it, or to leave it unchanged. Because renal clearance of lithium is reduced by thiazides, the risk of lithium toxicity is presumably raised further when, as in therapy with fosinopril sodium and hydrochlorothiazide tablets, a thiazide diuretic is coadministered with the ACE inhibitor. Fosinopril sodium and hydrochlorothiazide and lithium should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended.

Drug Interactions Potassium supplements and potassium-sparing diuretics As noted above (“Derangements of Serum Electrolytes”), the net effect of fosinopril sodium and hydrochlorothiazide may be to elevate a patient’s serum potassium, to reduce it, or to leave it unchanged. Because renal clearance of lithium is reduced by thiazides, the risk of lithium toxicity is presumably raised further when, as in therapy with fosinopril sodium and hydrochlorothiazide tablets, a thiazide diuretic is coadministered with the ACE inhibitor. Fosinopril sodium and hydrochlorothiazide and lithium should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended.

Antacid may impair absorption of fosinopril; dosing should be separated by 2 hours if concomitant use is necessary.

NSAIDs may reduce diuretic and antihypertensive effects of fosinopril sodium and hydrochlorothiazide; effects not fully studied.

May increase risk of hyperkalemia with fosinopril sodium and hydrochlorothiazide; concomitant use requires caution and frequent serum potassium monitoring.

Antacid component may impair absorption of fosinopril; dosing should be separated by 2 hours if concomitant use is necessary.

Potassium-sparing diuretic may increase risk of hyperkalemia when used with fosinopril sodium and hydrochlorothiazide; requires monitoring of serum potassium.

Potassium-sparing diuretic may increase risk of hyperkalemia when used with fosinopril sodium and hydrochlorothiazide; requires monitoring of serum potassium.

Other The bioavailability of unbound fosinoprilat is not altered by coadministration of fosinopril with aspirin, chlorthalidone, cimetidine, digoxin, metoclopramide, nifedipine, propranolol, propantheline, or warfarin .

Other The bioavailability of unbound fosinoprilat is not altered by coadministration of fosinopril with aspirin, chlorthalidone, cimetidine, digoxin, metoclopramide, nifedipine, propranolol, propantheline, or warfarin .

Other The bioavailability of unbound fosinoprilat is not altered by coadministration of fosinopril with aspirin, chlorthalidone, cimetidine, digoxin, metoclopramide, nifedipine, propranolol, propantheline, or warfarin .